Who are Active bevacizumab and Active dexamethasone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/active-bevacizumab-and-active-dexamethasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Active bevacizumab and Active dexamethasone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Active bevacizumab and Active dexamethasone (Active bevacizumab and Active dexamethasone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: monoclonal antibody (anti-VEGF) + corticosteroid. Area: Ophthalmology.

phase 2 Combination therapy: monoclonal antibody (anti-VEGF) + corticosteroid VEGF (bevacizumab); glucocorticoid receptor (dexamethasone) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Active bevacizumab and Active dexamethasone (Active bevacizumab and Active dexamethasone) — Texas Retina Associates. This combination uses bevacizumab to inhibit vascular endothelial growth factor (VEGF) and reduce abnormal blood vessel formation, while dexamethasone suppresses inflammation in the eye.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Active bevacizumab and Active dexamethasone TARGET	Active bevacizumab and Active dexamethasone	Texas Retina Associates	phase 2	Combination therapy: monoclonal antibody (anti-VEGF) + corticosteroid	VEGF (bevacizumab); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: monoclonal antibody (anti-VEGF) + corticosteroid class)

Texas Retina Associates · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Active bevacizumab and Active dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/active-bevacizumab-and-active-dexamethasone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab